Value Creation Model

We contribute to the healthier lives of people
around the world through the creation of pharmaceuticals.

Mitsubishi Tanabe Pharma was established in October 2007.
To contribute to the health of people around the world by offering new value,
we will continue to take on the challenge of opening up the future of healthcare.


We contribute to the healthier lives of people
around the world through the creation of pharmaceuticals.


Mitsubishi Tanabe Pharma's strengths backed by its achievements

The MTPC Group's strong drug discovery and drug fostering and evolution capabilities have resulted in the creation of many innovative pharmaceuticals.
Underpinning this are the relationships of trust with its stakeholders.
We will continue to provide society with new value based on our DNA to challenge and change backed by our more than 300 years of history.

  • Drug discovery capabilities / Drug fostering and evolution capabilities

  • Trust of patients and medical professionals

  • DNA to take on challenges and change

  • Core value chain as a traditional pharmaceutical company

Material issues

Seven material issues

  1. (1)

    Pharmaceuticals and healthcare services with differentiated value

  2. (2)

    Reliable products and sustainable supply

  3. (3)

    Appropriate use of products

  4. (4)

    Ethics, fairness and sincerity in business practices

  5. (5)

    Stakeholder engagement

  6. (6)

    Employee health, diversity and inclusion

  7. (7)

    Social contribution activities for health


Medium-Term Management Plan 16–20

Approach to Value Creation

Development Pipeline

Development pipeline to be the first to deliver differentiated value
Three growth drivers Features/Appeal
Radicava oral suspension
  • Development of suspension agent that is easy for ALS patients to take
  • Eliminates extended treatment time resulting from intravenous infusion administration
  • Eliminates limits on number of administration sites
Seasonal influenza Plant-based VLP vaccine
  • Shorter time for manufacture
  • Matches circulating strains (no egg adaptation)
  • Continuous subcutaneous injection stabilizes levodopa concentration in blood and improves time of onset of motor complications in Parkinson's disease patients

Modality and Digital

Modality and digital transformation to meet new medical needs

Using Modality

  • Focusing on modality in addition to conventional small molecules and antibodies.
  • Increasing and strengthening partnerships to generate new modalities.

Using AI

  • Streamlining clinical development by combining AI in information/data collection and AI in clinical trial design.

Providing Value to Society

Extension of healthy life expectancy

Raise the QOL of patients and their families

Contribute to QOL, which is to say, raise the quality of their life and living

Raise society's productivity

Contribute to increasing social productivity by providing superior pharmaceuticals and medical care services

Prevent disease

Contribute to maintaining people's health through vaccines that prevent infectious diseases and medical care to prevent the deterioration of patients' conditions